You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • THU0397 Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from a phase 3 extension trial (MEASURE 1)

Article metrics

Article menu

Download PDFPDF

Poster Presentations
Spondyloarthritis - treatment
THU0397 Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from a phase 3 extension trial (MEASURE 1)
Free

 

Online download statistics by month:

Online download statistics by month: June 2017 to March 2024

AbstractFullPdf
Jun 20171601
Jul 201744011
Aug 20173605
Sep 201790012
Oct 20173609
Nov 201748011
Dec 20174001
Jan 20183805
Feb 20182000
Mar 20182800
Apr 20182201
May 20182603
Jun 20183803
Jul 20183201
Aug 20182400
Sep 20182403
Oct 20181601
Nov 20181403
Dec 2018602
Jan 2019803
Feb 201916016
Mar 201928011
Apr 2019803
May 20191605
Jun 2019802
Jul 20191204
Aug 20191002
Sep 2019801
Oct 2019603
Nov 2019403
Dec 2019801
Jan 20201403
Feb 20204202
Mar 2020001
Apr 20202607
May 2020806
Jun 20201003
Jul 20201001
Aug 20201405
Sep 20202800
Oct 20202605
Nov 20201601
Dec 20201203
Jan 2021200
Feb 2021605
Mar 2021200
Apr 2021403
May 2021001
Jun 2021006
Jul 2021001
Sep 2021004
Oct 20216017
Nov 20217012
Dec 2021601
Jan 2022401
Feb 2022600
Mar 2022001
Apr 2022503
May 20221209
Jun 20221202
Jul 20221201
Aug 2022802
Sep 2022405
Oct 20221003
Nov 202218012
Dec 2022400
Jan 20231003
Feb 2023400
Mar 20231200
Apr 2023002
May 2023003
Jun 2023402
Jul 2023203
Aug 2023001
Sep 2023301
Oct 2023001
Nov 2023001
Dec 2023601
Jan 2024402
Feb 2024200
Mar 2024601
Total11170273